Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
17 May 1991Website:
http://www.ionispharma.comNext earnings report:
06 November 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 2 min agoDividend
Analysts recommendations
Institutional Ownership
IONS Latest News
Besides Wall Street's top -and-bottom-line estimates for Ionis Pharmaceuticals (IONS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.
Webcast scheduled for Wednesday, November 6 at 11:30 a.m. Eastern Time CARLSBAD, Calif.
AstraZeneca PLC (LSE:AZN) and Ionis Pharmaceuticals' (NASDAQ:IONS) drug Wainzua (eplontersen) has been recommended for approval in the European Union for treating hereditary transthyretin-mediated amyloidosis, a rare disease that damages nerves and leads to disability. The green light is based on a successful phase III trial, showing the drug improved patients' nerve function and quality of life compared to a placebo.
- Recommendation based on NEURO-TTRansform Phase 3 results showing WAINZUA demonstrated consistent and sustained benefit improving neuropathy impairment and quality of life versus placebo CARLSBAD, Calif. , Oct. 21, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that Ionis' and AstraZeneca's WAINZUA (eplontersen) has been recommended for approval by the Committee for Medicinal Products for Human Use (CHMP) in the European Union (EU) for the treatment of hereditary transthyretin-mediated amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy, commonly referred to as hATTR-PN or ATTRv-PN.
– Data continue to demonstrate donidalorsen potential to deliver significant and sustained reductions in HAE attacks up to three years with monthly or every two-month dosing CARLSBAD, Calif. , Oct. 3, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will present new three-year data from the Phase 2 open-label extension (OLE) study as well as additional results from the pivotal Phase 3 OASIS and OASISplus studies of donidalorsen, the company's investigational RNA-targeted prophylactic medicine for hereditary angioedema (HAE).
The FDA bestows a Fast Track designation to Ionis' investigational candidate, zilganersen, for treating a rare neurological disorder called Alexander disease.
IONS' shares fell after announcing the pricing of its secondary issue of shares, which were at a 12% discount to the previous closing price.
CARLSBAD, Calif. , Sept. 9, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced a proposed underwritten public offering of $500.0 million of its common stock.
CARLSBAD, Calif. , Aug. 28, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: 2024 Wells Fargo Healthcare Conference on Wednesday, September 4, 2024 Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, 2024 A live webcast of these presentations can be accessed on the Investors & Media section of the Ionis website at https://ir.ionis.com/events-and-presentations/upcoming-events.
Ionis Pharmaceuticals specializes in RNA-targeted therapies for neurological and cardiometabolic diseases using antisense DNA technology. The company has a robust pipeline with over 40 drug candidates, developed in partnership with major pharmaceutical companies and in-house. In 2024, Ionis launched Wainua for ATTRv-PN and Qalsody for SOD1-ALS, marking significant milestones in its product portfolio.
What type of business is Ionis Pharmaceuticals?
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, specializing in research and development of RNA-targeted therapy. It was founded in 1989. The product portfolio includes more than 40 potential drugs aimed at treating a wide range of therapeutic diseases. Currently, the company has three commercially approved drugs in major markets worldwide: SPINRAZA, TEGSEDI, and WAYLIVRA. There are also four drugs undergoing the company's main research: tominersen for Huntington's disease, tofersen for SOD1-ALS, AKCEA-APO(a)-L Rx for cardiovascular diseases, and AKCEA-TTR-L Rx for ATTR amyloidosis treatment.
What sector is Ionis Pharmaceuticals in?
Ionis Pharmaceuticals is in the Healthcare sector
What industry is Ionis Pharmaceuticals in?
Ionis Pharmaceuticals is in the Biotechnology industry
What country is Ionis Pharmaceuticals from?
Ionis Pharmaceuticals is headquartered in United States
When did Ionis Pharmaceuticals go public?
Ionis Pharmaceuticals initial public offering (IPO) was on 17 May 1991
What is Ionis Pharmaceuticals website?
https://www.ionispharma.com
Is Ionis Pharmaceuticals in the S&P 500?
No, Ionis Pharmaceuticals is not included in the S&P 500 index
Is Ionis Pharmaceuticals in the NASDAQ 100?
No, Ionis Pharmaceuticals is not included in the NASDAQ 100 index
Is Ionis Pharmaceuticals in the Dow Jones?
No, Ionis Pharmaceuticals is not included in the Dow Jones index
When was Ionis Pharmaceuticals the previous earnings report?
No data
When does Ionis Pharmaceuticals earnings report?
The next expected earnings date for Ionis Pharmaceuticals is 06 November 2024